^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

BCL2 expression

i
Other names: BCL2, Bcl-2, PPP1R50, B-cell CLL/lymphoma 2
Entrez ID:
4d
New trial
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
|
BCL2 expression • MYC expression
7d
Cytotoxic T-lymphocyte antigen 4 and programmed cell death ligand 1 blockade increases the effectiveness of interleukin-15 immunotherapy in a bovine leukemia model. (PubMed, Vet World)
Using rbIL15 with CTLA-4 and PD-L1 blockade in PBMCs from healthy and BLV+ cows led to the production of a transcription factor and cytokine. The results demonstrate the possibility of using this method to improve immunity and immunological memory in patients with chronic viral infections.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • BCL2 (B-cell CLL/lymphoma 2) • IFNG (Interferon, gamma) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • STAT3 (Signal Transducer And Activator Of Transcription 3) • IL15 (Interleukin 15) • STAT5A (Signal Transducer And Activator Of Transcription 5A)
|
BCL2 expression
8d
Isosteviol plays a protective role on hepatic ischemia and reperfusion injury in mice through MAPK/NF-κB signaling pathway. (PubMed, Transl Gastroenterol Hepatol)
Finally, ISV can reduce the phosphorylation level and activation of NF-κB, JNK, p38 and ERK. ISV inhibits the occurrence of inflammation and hepatocyte apoptosis through mitogen-activated protein kinase (MAPK)/NF-κB signaling pathway to relieve liver injury.
Preclinical • Journal • IO biomarker
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • ANXA5 (Annexin A5) • MPO (Myeloperoxidase)
|
BCL2 expression • BAX expression
9d
ECOG-ACRIN EA9152: Venetoclax and Vincristine in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov)
P1/2, N=74, Active, not recruiting, ECOG-ACRIN Cancer Research Group | Recruiting --> Active, not recruiting
Enrollment closed • Combination therapy • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2)
|
BCL2 expression
|
Venclexta (venetoclax) • vincristine • Marqibo (vincristine liposomal)
9d
Petunidin attenuates vinclozolin instigated testicular toxicity in albino rats via regulating TLR4/MyD88/TRAF6 and Nrf-2/Keap-1 pathway: A pharmacodynamic and molecular simulation approach. (PubMed, Int Immunopharmacol)
Lastly, molecular docking (MD) was performed to assess the effectiveness of PDN as a curative compound by analyzing its binding affinity with the targeted proteins (Keap1, TLR4 and StAR). Our in-silico evaluations confirmed that PDN possesses the potential to interact with binding pockets of these proteins, emphasizing its capability as a curative compound to mitigate VZN-prompted reproductive damage.
PK/PD data • Preclinical • Journal • IO biomarker
|
MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • KEAP1 (Kelch Like ECH Associated Protein 1) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • HMOX1 (Heme Oxygenase 1) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • TLR4 (Toll Like Receptor 4) • IL1B (Interleukin 1, beta) • CAT (Catalase) • TRAF6 (TNF Receptor Associated Factor 6)
|
KEAP1 mutation • BCL2 expression • BAX expression
9d
Tanshinone II A Facilitates Chemosensitivity of Osteosarcoma Cells to Cisplatin via Activation of p38 MAPK Pathway. (PubMed, Chin J Integr Med)
Tan II A synergizes with DDP by activating the p38/MAPK pathway to upregulate cleaved caspase-3 and Bax pro-apoptotic gene expressions, and downregulate caspase-3 and Bcl-2 inhibitory apoptotic gene expressions, thereby enhancing the chemosensitivity of osteosarcoma cells to DDP.
Journal • IO biomarker
|
CASP3 (Caspase 3) • ANXA5 (Annexin A5)
|
BCL2 expression
|
cisplatin
9d
Fucoidan Ameliorates Testosterone-Induced Benign Prostatic Hyperplasia (BPH) in Rats. (PubMed, Res Rep Urol)
Forty-eight Sprague Dawley (SD) rats were randomly divided into six groups; G1- vehicle control, G2- testosterone alone BPH control group (3 mg/kg), G3- finasteride (10 mg/kg) + testosterone, G4- fucoidan (40 mg/kg) + testosterone, G5- fucoidan (400 mg/kg) + testosterone, and G6- fucoidan alone (400 mg/kg)...Histopathological evidence revealed fewer microscopic lesions in the fucoidan groups compared to the BPH control group. The results suggest Undaria pinnatifida fucoidan can reduce testosterone-induced BPH symptoms in SD rats.
Preclinical • Journal • IO biomarker
|
TNFA (Tumor Necrosis Factor-Alpha) • BAX (BCL2-associated X protein) • IL1B (Interleukin 1, beta)
|
BCL2 expression • BAX expression
|
finasteride
10d
Phenolics in soymilk manufactured from black and Proto soybeans by two continuous-ultrahigh-temperature-processing technologies inhibit DU145-prostate cancer cell proliferation through apoptosis. (PubMed, J Food Sci)
The crude extract can be prepared much less costly than purified isoflavones and has potential to be developed into a dietary supplement. This study shows differences of soymilks made by continuous high-temperature processing of two soybean types and can serve as a scientific foundation for future clinical research and commercialization.
Journal • PARP Biomarker • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • PARP1 (Poly(ADP-Ribose) Polymerase 1) • CASP3 (Caspase 3)
|
BCL2 expression • PARP1 expression
10d
The role of NOP58 in prostate cancer progression through SUMOylation regulation and drug response. (PubMed, Front Pharmacol)
Additionally, NOP58 was linked to drug responses, including Methotrexate, Rapamycin, Sorafenib, and Vorinostat. Its expression level serves as a reliable prognostic biomarker and an actionable therapeutic target, advancing precision medicine for prostate cancer. Targeting NOP58 may enhance therapeutic efficacy and improve outcomes in oncology.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2)
|
BCL2 expression
|
sorafenib • methotrexate • sirolimus • Zolinza (vorinostat)
10d
Real-world efficacy of chidamide plus R-CHOP in newly diagnosed double-expressor diffuse large B-cell lymphoma. (PubMed, Ther Adv Hematol)
To evaluate the efficacy of a novel histone deacetylase inhibitor, chidamide, in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (CR-CHOP) in the treatment of DEL. The most common grades 3-4 hematologic and nonhematologic toxicity were leukopenia (46.7%) and infection (21%), respectively. This long-term follow-up study indicates that CR-CHOP in untreated DLBCL with the DEL phenotype demonstrates high short-term efficacy and safety as well as promising survival outcomes.
Journal • Real-world evidence • IO biomarker • Real-world effectiveness • Real-world
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2)
|
BCL2 expression • MYC expression
|
Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Epidaza (chidamide)
10d
The effect of L-carnitine in reactive oxygen species reduction and apoptotic gene expression in mice after cyclophosphamide: An experimental study. (PubMed, Int J Reprod Biomed)
LC decreased the ROS level in the LC+CP group compared to the CP group (p 0.001). Findings suggest that LC can scavenge the ROS caused by CP and modulate the apoptotic pathway via downregulating the Bax and Caspase3 genes and upregulating the Bcl2 gene in oocytes of mice exposed to CP.
Preclinical • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3)
|
BCL2 expression • BAX expression
|
cyclophosphamide
10d
Enhancement of the Sensitivity of the Acute Lymphoblastic Leukemia Cells to ABT-737 by Formononetin. (PubMed, Int J Mol Cell Med)
In summary, formononetin showed anti-carcinogenic activities in human ALL cells via suppression of cell growth and survival. Formononetin enhanced the apoptotic effect of ABT-737, with contribution by inhibition of the Mcl-1 expression.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
|
BCL2 expression • MCL1 expression • BAX expression
|
ABT-737
10d
The prognostic significance of MYC/BCL2 double expression in DLBCL in the genetic classification era. (PubMed, Cancer Sci)
DEL showed similarities with the MCD subtype in mutation profiles. Furthermore, RNA-sequencing analyses exhibited upregulation in tumor proliferation-related pathways in DEL patients, but downregulation in extracellular matrix organization, T-cell activation and proliferation, type II interferon production, and pathways associated with cell death might contribute to the poor outcomes of DEL patients.
Journal • IO biomarker
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2)
|
BCL2 expression • MYC expression
10d
Associations between BCL-2 expression and different histopathological prognostic factors in different molecular subtypes of invasive breast carcinoma of no special type. (PubMed, Histol Histopathol)
BCL-2 expression in IBC; NST has different prognostic effects depending on the molecular subtype of the cancer. In cancers with a HER2-enriched phenotype, BCL-2 expression was a marker of poor prognosis, while in cancers with a hormone receptor-positive phenotype, BCL-2 expression had a better prognostic impact.
Journal • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • BCL2 (B-cell CLL/lymphoma 2)
|
HR positive • HER-2 negative • BCL2 expression • BCL2 positive
11d
Alpha-Linolenic Acid Supplementation Improves Testosterone Production in an Aged Breeder Rooster Model: Role of Mitochondrial Modulation and SIRT1 Activation. (PubMed, Mol Nutr Food Res)
These findings indicate that dietary supplementation with ALA can improve testosterone production in aged breeder roosters, possibly by modulation of mitochondrial function via activating the SIRT1 pathway.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2)
|
BCL2 expression
11d
BCL-2 and γ-H2AX immunostaining profile in urothelial bladder cancer prognosis. (PubMed, Pathol Res Pract)
No significant correlation was found between protein profiles in malignant tissue. All in all, BCL-2 and γ-H2AX did not prove to be candidate markers for UBC clinical management in the present sample, despite their expression in malignant bladder tissue.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • H2AX (H2A.X Variant Histone)
|
BCL2 expression
12d
The combination of venetoclax and quercetin exerts a cytotoxic effect on acute myeloid leukemia. (PubMed, Sci Rep)
We found that quercetin increased Bcl-2-associated X protein (Bax) expression in KG-1. Our study provides a novel function for quercetin and presents a promising strategy for AML treatment using venetoclax.
Journal • PARP Biomarker • IO biomarker
|
BAX (BCL2-associated X protein)
|
BCL2 expression • BAX expression
|
Venclexta (venetoclax)
13d
Preventive effects of coixol, an active compound of adlay seed, in NGF-differentiated PC12 cells against beta-amyloid25-35-induced neurotoxicity. (PubMed, Asian Biomed (Res Rev News))
Coixol treatments at 0.5-2 μM increased protein generation of nuclear factor E2-related factor 2, and limited protein production of inducible nitric oxide synthase and receptor of advanced glycation end product. Our novel findings suggested that coixol was a compelling agent against beta-amyloid peptide-induced neurotoxicity.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • APP (Amyloid Beta Precursor Protein) • CAT (Catalase)
|
BCL2 expression • BAX expression
14d
The effects of Fe3O4NPs@SiO2 and Fe3O4NPs@pectin nanoparticles on the MCF-7 breast cancer cell line and the expression of BAX, TPX1 and BCL2 genes. (PubMed, Int J Biol Macromol)
Down-regulated expression of BCL2 showed a significant relationship between the three groups treated with 250 μg/mL and 500 μg/mL of Fe3O4@SiO2 and 250 μg/mL of Fe3O4@pectin (p-values of 0.0014, 0.0009 and 0.0030, respectively). Additionally, decreased TPX indicated a significant relationship between treatment at 125, 250 and 500 μg/mL of Fe3O4@SiO2 (p-values of 0.0388, 0.0063 and 0.0496, respectively).
Preclinical • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein)
|
BCL2 expression • BAX expression
14d
H2S-releasing oridonin derivatives with improved antitumor activity by inhibiting the PI3K/AKT pathway. (PubMed, Bioorg Med Chem)
It also inhibited the PI3K/AKT pathway to regulate the expression of Bax and Bcl-2, thereby initiating the Caspase cascade to activate mitochondrial mediated apoptosis. Furthermore, 11a suppressed tumor growth in breast cancer syngeneic models with no apparent toxicity.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein)
|
BCL2 expression • BAX expression
14d
Mechanism of Huayu Jiedu Decoction in Inhibiting Malignant Biological Characteristics of Multiple Myeloma (PubMed, Zhongguo Shi Yan Xue Ye Xue Za Zhi)
Huayu Jiedu Decoction can inhibit the proliferative activity of U266 cells and induce programmed death. Its molecular mechanism may be related to regulating the expression of apoptotic proteins, inhibiting the activation of TLR4/NF-κB pathway and down-regulating the expression of HMGB1 and IL-6 mRNA.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CXCR4 (Chemokine (C-X-C motif) receptor 4) • IL6 (Interleukin 6) • BIRC5 (Baculoviral IAP repeat containing 5) • BAX (BCL2-associated X protein) • HMGB1 (High Mobility Group Box 1) • ANXA5 (Annexin A5)
|
BCL2 expression • BIRC5 expression • BAX expression • CXCR4 expression • IL6 expression
14d
Establishment of BCL-2 Inhibitors-Resistant B-cell Acute Lymphoblastic Leukemia Cell Lines and Study on Their Resistance Mechanisms (PubMed, Zhongguo Shi Yan Xue Ye Xue Za Zhi)
Drug-resistant B-ALL cell lines could be successfully established by exposing RS4;11 cell line to the ascending concentration of BCL-2 inhibitors, and the drug resistance mechanism may be related to the overexpression of EP300.
Preclinical • Journal • IO biomarker
|
EP300 (E1A binding protein p300)
|
BCL2 expression • EP300 overexpression
|
Venclexta (venetoclax) • navitoclax (ABT 263)
14d
Chidamide Combined with (+) -JQ-1 to Kill MLL-Rearrangement Acute Myeloid Leukemia Cells by Disrupting the DNA Damage Response Pathway (PubMed, Zhongguo Shi Yan Xue Ye Xue Za Zhi)
Chidamide combined with (+)-JQ-1 can inhibit the proliferation of MLL-r AML cells, inhibit the initiation of protective self-repair of these leukemia cells by inhibiting the DNA damage response pathway, and ultimately increase the apoptosis of these cells, but non- MLL-r AML cells have no similar results.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • KMT2A (Lysine Methyltransferase 2A) • CHEK2 (Checkpoint kinase 2) • RAD51 (RAD51 Homolog A) • CHEK1 (Checkpoint kinase 1) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • BRD4 (Bromodomain Containing 4) • TP53BP1 (Tumor Protein P53 Binding Protein 1)
|
MLL rearrangement • MLL rearrangement • BCL2 expression • BAX expression
|
JQ-1 • Epidaza (chidamide)
14d
Isothiocyanates attenuate heparin-induced proliferation of colon cancer cells in vitro. (PubMed, Food Sci Nutr)
PEITC, BITC, and SFN also increased proapoptotic Bax expression and decreased the antiapoptotic B-cell lymphoma 2 (Bcl-2) expression (all, p < .05). These findings suggest that specific ITCs may mitigate cancer cell proliferation induced by LMWH in cancer therapies, highlighting their potential therapeutic efficacy.
Preclinical • Journal • IO biomarker
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • BCL2 (B-cell CLL/lymphoma 2) • ERBB4 (erb-b2 receptor tyrosine kinase 4) • BAX (BCL2-associated X protein) • TGFB1 (Transforming Growth Factor Beta 1)
|
HER-2 expression • BCL2 expression • BAX expression
15d
Overcoming multi-drug resistance in SCLC: a synergistic approach with venetoclax and hydroxychloroquine targeting the lncRNA LYPLAL1-DT/BCL2/BECN1 pathway. (PubMed, Mol Cancer)
Our findings demonstrate that upregulation of LYPLAL1-DT sequesters apoptosis through the LYPLAL1-DT/miR-204-5p/BCL2 axis and promotes autophagy by facilitating the assembly of the BECN1/PtdIns3K complex, thereby mediating multi-drug resistance of SCLC. The triple combination of venetoclax, HCQ, in conjunction with cDDP, VP-16 or PTX overcomes refractory SCLC, shedding light on a potential therapeutic target for combating SCLC chemoresistance.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BECN1 (Beclin 1) • MIR204 (MicroRNA 204)
|
BCL2 expression
|
Venclexta (venetoclax) • hydroxychloroquine
15d
Antioxidant, cytotoxic, anti-migratory, and pro-apoptotic effects of Bolanthus turcicus extracts on head and neck cancer cells. (PubMed, Mol Biol Rep)
This study data indicated that B. turcicus extracts have antioxidant, cytotoxic, anti-migratory and pro-apoptotic activity. In conclusion, it has been shown that B. turcicus can be used as a potential therapeutic agent against HNC.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • ANXA5 (Annexin A5)
|
BCL2 expression • BAX expression
15d
Characterizing and Targeting of BCL-2 Family Members in Nasopharyngeal Carcinoma. (PubMed, Head Neck)
Our study demonstrates the therapeutic potential of combining cisplatin and S63845, which warrants further investigation.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • MCL1 (Myeloid cell leukemia 1) • BCL2L1 (BCL2-like 1)
|
BCL2 expression • MCL1 expression
|
Venclexta (venetoclax) • cisplatin • S63845 • ABT-737
15d
Hypericin and Naringenin Exert no Significant Synergistic Apoptotic Effect on Y79 Retinoblastoma Cell Line. (PubMed, Galen Med J)
Hypericin had more cytotoxic effect in Y79 cells compared with naringenin. Furthermore, hypericin and naringenin didn't have apoptotic synergistic effect in these cells. According to the real-time PCR results, hypericin induces apoptosis in Y79 cells by disrupt the ratio of Bax/Bcl-2.
Preclinical • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • ANXA5 (Annexin A5)
|
BCL2 expression • BAX expression
15d
Pterostilbene suppresses head and neck cancer cell proliferation via induction of apoptosis. (PubMed, Turk J Biol)
Moreover, PS displayed a significant suppressive efficacy on the migration capacity of HNC cells. The present study provides proof that PS has the prospective to be improved as an attractive anticancer agent against HNC following advanced studies.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • ANXA5 (Annexin A5)
|
BCL2 expression • BAX expression
15d
Banxia xiexin decoction prevents the development of gastric cancer. (PubMed, World J Clin Oncol)
BXD has the effect of inhibiting tumor growth rate and delaying the development of GC. Its mechanism of action may be related to the regulation of PI3K-Akt signaling pathway.
Journal • IO biomarker
|
EGFR (Epidermal growth factor receptor) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • BCL2 (B-cell CLL/lymphoma 2) • IL6 (Interleukin 6)
|
EGFR expression • BCL2 expression • IL6 expression
|
capecitabine • LY294002
15d
GRK2 Protein Mediates the ANRIL, a lncRNA, to Affect the Proliferation and Apoptosis of Kasumi-1 Cells. (PubMed, Front Biosci (Landmark Ed))
The GRK2 protein-mediated ANRIL, increasing Kasumi-1 cell proliferation and inhibiting apoptosis by activating the PI3K/AKT/BCL-2 pathway.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CASP3 (Caspase 3) • PCNA (Proliferating cell nuclear antigen)
|
BCL2 expression • BAX expression • PCNA expression
16d
Overexpression of SLAP2 inhibits triple-negative breast cancer progression by promoting macrophage M1-type polarization. (PubMed, Sci Rep)
By transwell co-culture system, we further demonstrated that overexpression of SLAP2 inhibits cell proliferation and invasion, promotes apoptosis, up-regulates the expression of Bax in cells, and down-regulates the expression of Bcl-2 in cells by promoting macrophage M1-type polarization. Overexpression of SLAP2 inhibits TNBC progression by promoting macrophage M1-type polarization.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • HSP90AA1 (Heat Shock Protein 90 Alpha Family Class A Member 1Heat Shock Protein 90 Alpha Family Class A Member 1)
|
BCL2 expression • BAX expression
16d
MiR-34c-5p Inhibition Affects Bax/Bcl2 Expression and Reverses Bortezomib Resistance in Multiple Myeloma Cells. (PubMed, Indian J Hematol Blood Transfus)
Our findings demonstrate miR-34c-5p is differentially expressed between bortezomib-sensitive and -resistant MM cells. Inhibiting miR-34c-5p re-sensitized resistant cells to bortezomib by modulating Bax/Bcl-2 expression, suggesting this miRNA regulates apoptosis and drug resistance and may be a promising therapeutic target for overcoming proteasome inhibitor resistance in MM.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • XBP1 (X-box-binding protein 1) • MIR214 (MicroRNA 214) • MIR30C
|
BCL2 overexpression • BCL2 expression • BAX expression
|
bortezomib
16d
The Comparative Effect of Plasma Exosomes of Young and Old People on the Expression of BCL-2 and BAX Genes in Hematopoietic Stem Cells. (PubMed, Indian J Hematol Blood Transfus)
The BAX gene was significantly upregulated and the BCL-2 gene was significantly downregulated after utilizing the exosomes derived from the plasma of elderly individuals (dose 10 µg/ml) compared to the control (P = 0.001, P = 0.002, respectively). The current research shows that aged people's exosomes can increase BAX/ BCL-2 ratio in umbilical cord blood-derived HSCs compared to control and young groups.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein)
|
BCL2 expression • BAX expression
16d
The mechanism of paclitaxel induced damage on placental trophoblast cells. (PubMed, BMC Pregnancy Childbirth)
Paclitaxel may directly or indirectly affect the normal physiological functions of placental trophoblast cells, including energy metabolism and protein synthesis dysfunction, which may be related to the adverse pregnancy outcomes caused by paclitaxel chemotherapy.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein)
|
BCL2 expression • BAX expression
|
paclitaxel
17d
Chemopreventive potential of goniothalamin in diethylnitrosamine-induced hepatocellular carcinoma through the suppression of P13K/AKT signalling pathway. (PubMed, Korean J Physiol Pharmacol)
These findings revealed that GTN subdues the P13K/AKT pathway and has auspicious chemopreventive and apoptotic actions in DEN-induced HCC. Therefore, GTN would be suggested as a new medicine in natural remedies for liver cancer.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CASP3 (Caspase 3)
|
BCL2 expression • CASP3 elevation
18d
Experimental study on the treatment of diabetic cardiomyopathy in rats by using ultrasound-targeted microbubble destruction combined with coenzyme Q10 loaded long-circulating nanoliposomes (PubMed, Zhonghua Yi Xue Za Zhi)
In the CoQ10-PEG-Lips+UTMD group, the levels of myocardial superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), and the expression of the anti-apoptotic protein B-cell lymphoma-2 (Bcl-2) were significantly higher compared to the DM model group, CoQ10 solution group, and CoQ10-PEG-Lips group (all P<0.05), while malondialdehyde levels and the expression of Bcl-2-associated X protein (Bax) and caspase-3 were lower (all P<0.05). Using PEG-lips to encapsulate the poorly soluble drug CoQ10 in combination with UTMD technology enables targeted delivery of the drug to the myocardium, which can help reduce myocardial cell damage, fibrosis, and apoptosis caused by diabetes mellitus (DM) by inhibiting oxidative stress damage and the Bcl-2/Bax/caspase-3 apoptosis signaling pathway, ultimately improving cardiac function in DCM rats.
Preclinical • Journal • IO biomarker
|
CASP3 (Caspase 3)
|
BCL2 expression • BAX expression
18d
SIRT2 Alleviates Inflammatory Response, Apoptosis, and ECM Degradation in Osteoarthritic Chondrocytes by Stabilizing PCK1. (PubMed, Discov Med)
SIRT2 inhibits articular chondrocyte extracellular matrix (ECM) degradation, inflammatory factor expression, and apoptosis via PCK1.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • IL1B (Interleukin 1, beta) • ACAN (Aggrecan) • PCK1 (Phosphoenolpyruvate Carboxykinase 1) • SIRT2 (Sirtuin 2)
|
BCL2 expression
19d
Thiazolidinedione-Conjugated Lupeol Derivatives as Potent Anticancer Agents Through a Mitochondria-Mediated Apoptotic Pathway. (PubMed, Molecules)
Western blot analysis suggested that compound 12i can upregulate Bax expression, downregulate Bcl-2 expression, and activate the mitochondria-mediated apoptotic pathway. Collectively, compound 12i is worthy of further investigation to support the discovery of effective agents against cancer.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • ANXA5 (Annexin A5)
|
BCL2 expression • BAX expression
19d
Insights into Clematis cirrhosa L. Ethanol Extract: Cytotoxic Effects, LC-ESI-QTOF-MS/MS Chemical Profiling, Molecular Docking, and Acute Toxicity Study. (PubMed, Pharmaceuticals (Basel))
These outcomes point to the potential of Clematis cirrhosa as a promising candidate for further exploration in cancer therapy.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • KDR (Kinase insert domain receptor) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3)
|
BCL2 expression • BAX expression
19d
Development of Quercetin Solid Dispersion-Loaded Dissolving Microneedles and In Vitro Investigation of Their Anti-Melanoma Activities. (PubMed, Pharmaceutics)
It suppressed Bcl-2 gene expression and led to a lower content of Bcl-2 in the cells. The optimized Q-SD-DMN has a potential for use in further in vivo studies as a synergistic method of melanoma treatment.
Preclinical • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2)
|
BCL2 expression
19d
Targeting Oxidative Stress: The Potential of Vitamin C in Protecting against Liver Damage after Electron Beam Therapy. (PubMed, Biomedicines)
It effectively reduced oxidative stress, apoptosis, and inflammation, particularly in preventing the progression of radiation-induced liver fibrosis. These findings suggest that vitamin C could enhance radiotherapy outcomes by minimizing liver damage, warranting further exploration into its broader clinical applications.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • IL1B (Interleukin 1, beta)
|
BCL2 expression • BAX expression